Roche exercises option for Recursion's Microglia Map; $30M fee

RECURSION PHARMACEUTICALS, INC.

Roche exercised option for a first-of-its-kind whole genome map of brain immune cells (Microglia Map) from Recursion.
Recursion will receive a $30 million Acceptance Fee from Roche under the 2021 Collaboration and License Agreement.
The Microglia Map is generated by Recursion's platform as part of the ongoing partnership with Roche.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.